Pathology Reporting in Neuroendocrine Neoplasms of the Digestive System: Everything You Always Wanted to Know but Were Too Afraid to Ask
暂无分享,去创建一个
A. Colao | A. Faggiano | F. Grillo | G. Puliani | M. Albertelli | F. Lo Calzo | C. Rainone | Barbara Luigi Filomena Severo Federica Sergio Alessandra C Altieri Barrea Bottiglieri Campione De Ci
[1] A. Vanoli,et al. Neuroendocrine neoplasms of the appendix, colon and rectum , 2021, Pathologica.
[2] U. Pastorino,et al. Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis , 2020, Neuroendocrinology.
[3] A. Kjaer,et al. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms , 2020, BMC Cancer.
[4] A. Bellizzi. Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can Brown do for you? , 2019, Human pathology.
[5] Peter Schirmacher,et al. The 2019 WHO classification of tumours of the digestive system , 2019, Histopathology.
[6] D. Klimstra,et al. Classification of neuroendocrine neoplasms of the digestive system , 2019 .
[7] A. Barbieri,et al. Grading Pancreatic Neuroendocrine Tumors by Ki-67 Index Evaluated on Fine-Needle Aspiration Cell Block Material. , 2019, American journal of clinical pathology.
[8] He Xiao,et al. Value of SATB2, ISL1, and TTF1 to differentiate rectal from other gastrointestinal and lung well-differentiated neuroendocrine tumors. , 2019, Pathology, research and practice.
[9] S. Schulz,et al. Different somatostatin and CXCR4 chemokine receptor expression in gastroenteropancreatic neuroendocrine neoplasms depending on their origin , 2019, Scientific Reports.
[10] J. Cates,et al. Should Ki67 immunohistochemistry be performed on all lesions in multifocal small intestinal neuroendocrine tumours? , 2018, Histopathology.
[11] Petar Noack,et al. Accuracy of grading pancreatic neuroendocrine neoplasms with Ki‐67 index in fine‐needle aspiration cellblock material , 2018, Cytopathology : official journal of the British Society for Clinical Cytology.
[12] Song-Cheol Kim,et al. Grading by the Ki-67 Labeling Index of Endoscopic Ultrasound–Guided Fine Needle Aspiration Biopsy Specimens of Pancreatic Neuroendocrine Tumors Can Be Underestimated , 2018, Pancreas.
[13] J. Zedenius,et al. Regional differences in somatostatin receptor 2 (SSTR2) immunoreactivity is coupled to level of bowel invasion in small intestinal neuroendocrine tumors. , 2018, Neuro endocrinology letters.
[14] M. Ruchała,et al. Pasireotide - Mechanism of Action and Clinical Applications. , 2018, Current drug metabolism.
[15] L. Mazzucchelli,et al. Mixed Adenoma Well-differentiated Neuroendocrine Tumor (MANET) of the Digestive System: An Indolent Subtype of Mixed Neuroendocrine-NonNeuroendocrine Neoplasm (MiNEN) , 2018, The American journal of surgical pathology.
[16] A. Vanoli,et al. Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis. , 2018, Endocrine-related cancer.
[17] Hong-Jin Kim,et al. Grading Using Ki-67 Index and Mitotic Rate Increases the Prognostic Accuracy of Pancreatic Neuroendocrine Tumors , 2018, Pancreas.
[18] W. Ito,et al. High interlaboratory and interobserver agreement of somatostatin receptor immunohistochemical determination and correlation with response to somatostatin analogs. , 2018, Human pathology.
[19] R. Luque,et al. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors , 2018, Endocrine.
[20] Wenchuan Wu,et al. Clinical relevance of different WHO grade 3 pancreatic neuroendocrine neoplasms based on morphology , 2018, Endocrine connections.
[21] Xiujun Cai,et al. Prognostic significance of cytokeratin 19 expression in pancreatic neuroendocrine tumor: A meta-analysis , 2017, PloS one.
[22] J. Cave,et al. Clinically Significant Differences in Ki-67 Proliferation Index Between Primary and Metastases in Resected Pancreatic Neuroendocrine Tumors , 2017, Pancreas.
[23] H. Ono,et al. Can the Ki-67 Labeling Index in Biopsy Specimens Predict the World Health Organization Grade of Rectal Neuroendocrine Tumors? , 2017, Digestive Diseases.
[24] A. Vanoli,et al. KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment? , 2017, Endocrine.
[25] P. Illei,et al. INSM1 Demonstrates Superior Performance to the Individual and Combined Use of Synaptophysin, Chromogranin and CD56 for Diagnosing Neuroendocrine Tumors of the Thoracic Cavity , 2017, The American journal of surgical pathology.
[26] Laura H. Tang,et al. Immunohistochemical Characterization of the Origins of Metastatic Well-differentiated Neuroendocrine Tumors to the Liver , 2017, The American journal of surgical pathology.
[27] T. Morikawa,et al. Diagnosis, Assessment, and Therapeutic Strategy for Colorectal Mixed Adenoneuroendocrine Carcinoma , 2017, Neuroendocrinology.
[28] A. Bellizzi,et al. Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival , 2017, Annals of Surgical Oncology.
[29] S. H. Lee,et al. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors , 2017, Oncotarget.
[30] B. Weynand,et al. Accuracy of Pancreatic Neuroendocrine Tumour Grading by Endoscopic Ultrasound-Guided Fine Needle Aspiration: Analysis of a Large Cohort and Perspectives for Improvement , 2017, Neuroendocrinology.
[31] S. Fanti,et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging , 2017, Neuroendocrinology.
[32] M. Pavel,et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors , 2017, Neuroendocrinology.
[33] R. Jensen,et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology - Diagnosis and Prognostic Stratification , 2017, Neuroendocrinology.
[34] Minhu Chen,et al. Somatostatin receptor expression indicates improved prognosis in gastroenteropancreatic neuroendocrine neoplasm, and octreotide long-acting release is effective and safe in Chinese patients with advanced gastroenteropancreatic neuroendocrine tumors , 2017, Oncology letters.
[35] J. Berlin,et al. Phase 3 Trial of 177Lu‐Dotatate for Midgut Neuroendocrine Tumors , 2017, The New England journal of medicine.
[36] W. Weichert,et al. Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20% , 2017, Modern Pathology.
[37] M. Kloor,et al. Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas , 2017, Modern Pathology.
[38] N. Fazio,et al. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. , 2016, Cancer treatment reviews.
[39] P. Ruszniewski,et al. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement. , 2016, The oncologist.
[40] Xihong Lin,et al. Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors , 2016, Pancreas.
[41] Laura H. Tang,et al. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas , 2016, The American journal of surgical pathology.
[42] R. Brand,et al. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors , 2016, Clinical Cancer Research.
[43] F. Grillo,et al. Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible? , 2016, Endocrine.
[44] Anthony A. Hyman,et al. Ki-67 acts as a biological surfactant to disperse mitotic chromosomes , 2016, Nature.
[45] T. Nagayasu,et al. Expression of Somatostatin Receptor Type 2A and PTEN in Neuroendocrine Neoplasms Is Associated with Tumor Grade but Not with Site of Origin , 2016, Endocrine Pathology.
[46] D. Nonaka,et al. Diagnostic Utility of Orthopedia Homeobox (OTP) in Pulmonary Carcinoid Tumors , 2016, The American journal of surgical pathology.
[47] F. Sessa,et al. Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs): Unifying the Concept of a Heterogeneous Group of Neoplasms , 2016, Endocrine Pathology.
[48] P. Ruszniewski,et al. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study , 2016, Endocrine-related cancer.
[49] M. Sampedro-Núñez,et al. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors , 2015, Oncotarget.
[50] R. Lloyd,et al. INSM1: A Novel Immunohistochemical and Molecular Marker for Neuroendocrine and Neuroepithelial Neoplasms. , 2015, American journal of clinical pathology.
[51] R. Fiocca,et al. Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor , 2015, Neuroendocrinology.
[52] M. Daleo,et al. Discordance of Histologic Grade Between Primary and Metastatic Neuroendocrine Carcinomas , 2015, Annals of Surgical Oncology.
[53] Michael Goodman,et al. Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies , 2015, Modern Pathology.
[54] Toby C. Cornish,et al. Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors. , 2015, American journal of clinical pathology.
[55] A. Bellizzi,et al. A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors. , 2014, Surgery.
[56] M. V. van Velthuysen,et al. Grading of Neuroendocrine Neoplasms: Mitoses and Ki-67 Are Both Essential , 2014, Neuroendocrinology.
[57] M. V. van Velthuysen,et al. Reliability of Proliferation Assessment by Ki-67 Expression in Neuroendocrine Neoplasms: Eyeballing or Image Analysis? , 2014, Neuroendocrinology.
[58] A. Krasinskas,et al. Poorly Differentiated Neuroendocrine Carcinomas of the Pancreas: A Clinicopathologic Analysis of 44 Cases , 2014, The American journal of surgical pathology.
[59] E. Speel,et al. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors. , 2014, Gastroenterology.
[60] C. Sempoux,et al. Pancreatic neuroendocrine tumour grading on endoscopic ultrasound‐guided fine needle aspiration: high reproducibility and inter‐observer agreement of the Ki‐67 labelling index , 2013, Cytopathology : official journal of the British Society for Clinical Cytology.
[61] Toby C. Cornish,et al. Grading of Well-differentiated Pancreatic Neuroendocrine Tumors Is Improved by the Inclusion of Both Ki67 Proliferative Index and Mitotic Rate , 2013, The American journal of surgical pathology.
[62] Xiaoyan Zhou,et al. The Immunohistochemical Expression of Islet 1 and PAX8 by Rectal Neuroendocrine Tumors Should Be Taken into Account in the Differential Diagnosis of Metastatic Neuroendocrine Tumors of Unknown Primary Origin , 2013, Endocrine Pathology.
[63] A. Bellizzi. Assigning Site of Origin in Metastatic Neuroendocrine Neoplasms: A Clinically Significant Application of Diagnostic Immunohistochemistry , 2013, Advances in anatomic pathology.
[64] T. Smyrk,et al. Islet-1 Is a Sensitive But Not Entirely Specific Marker for Pancreatic Neuroendocrine Neoplasms and Their Metastases , 2013, The American journal of surgical pathology.
[65] Laura H. Tang,et al. Objective Quantification of the Ki67 Proliferative Index in Neuroendocrine Tumors of the Gastroenteropancreatic System: A Comparison of Digital Image Analysis With Manual Methods , 2012, The American journal of surgical pathology.
[66] Hanlin L. Wang,et al. Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin , 2012, Modern Pathology.
[67] D. Jain,et al. PDX-1, CDX-2, TTF-1, and CK7: A Reliable Immunohistochemical Panel for Pancreatic Neuroendocrine Neoplasms , 2012, The American journal of surgical pathology.
[68] Run Yu,et al. Ki-67 proliferative index predicts progression-free survival of patients with well-differentiated ileal neuroendocrine tumors. , 2012, Human pathology.
[69] F. Sessa,et al. Mixed Adenoneuroendocrine Carcinomas (MANECs) of the Gastrointestinal Tract: An Update , 2012, Cancers.
[70] A. Sangoi,et al. PAX8 is expressed in pancreatic well‐differentiated neuroendocrine tumors and in extrapancreatic poorly differentiated neuroendocrine carcinomas in fine‐needle aspiration biopsy specimens , 2011, Cancer cytopathology.
[71] Michael A. Choti,et al. DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors , 2011, Science.
[72] Andrew H. Beck,et al. PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma , 2011, Modern Pathology.
[73] M. Hirsch,et al. PAX8 Expression in Well-differentiated Pancreatic Endocrine Tumors: Correlation With Clinicopathologic Features and Comparison With Gastrointestinal and Pulmonary Carcinoid Tumors , 2010, The American journal of surgical pathology.
[74] G. Pelosi,et al. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[75] C. Lohse,et al. KIT is an Independent Prognostic Marker for Pancreatic Endocrine Tumors: A Finding Derived From Analysis of Islet Cell Differentiation Markers , 2009, The American journal of surgical pathology.
[76] Amitabh Srivastava,et al. Immunohistochemical Staining for CDX-2, PDX-1, NESP-55, and TTF-1 Can Help Distinguish Gastrointestinal Carcinoid Tumors From Pancreatic Endocrine and Pulmonary Carcinoid Tumors , 2009, The American journal of surgical pathology.
[77] H. Moch,et al. Islet 1 (Isl1) Expression is a Reliable Marker for Pancreatic Endocrine Tumors and Their Metastases , 2008, The American journal of surgical pathology.
[78] F. Schmidt. Meta-Analysis , 2008 .
[79] M. Papotti,et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy , 2007, Modern Pathology.
[80] C. Capella,et al. Prognostic and biological significance of cytokeratin 19 in pancreatic endocrine tumours , 2007, Histopathology.
[81] A. Saqi,et al. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids. , 2005, American journal of clinical pathology.
[82] V. Deshpande,et al. Cytokeratin 19 Is a Powerful Predictor of Survival in Pancreatic Endocrine Tumors , 2004, The American journal of surgical pathology.
[83] S. Lamberts,et al. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. , 2003, Endocrine-related cancer.
[84] L. Aaltonen,et al. Pathology and genetics of tumours of the digestive system , 2000 .
[85] S M Powsner,et al. Clinicians are from Mars and pathologists are from Venus. , 2000, Archives of pathology & laboratory medicine.
[86] M. Tsuneyoshi,et al. Malignant smooth muscle tumors of the retroperitoneum and mesentery: A clinicopathologic analysis of 44 cases , 1985, Journal of surgical oncology.
[87] H. Sorbye,et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[88] G. Petris,et al. Objective Quantification of the Ki67 Proliferative Index in Neuroendocrine Tumors of the Gastroenteropancreatic System: A Comparison of Digital Image Analysis With Manual Methods , 2013 .
[89] J. Laissue,et al. Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands , 2001, European Journal of Nuclear Medicine.
[90] K. Johnson. An Update. , 1984, Journal of food protection.